Phenotypes Associated with This Genotype

Genotype
MGI:7738261

cn2

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Ptf1a^tm1(cre)Hnak/Ptf1a⁺; Ube2f^{tm1c(EUCOMM)Hmgu}/Ube2f^{tm1c(EUCOMM)Hmgu}
• Genetic Background: involves: 129S4/SvJae * C57BL/6J * C57BL/6N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

increased body weight ( J:348744 )

• relative to mutant mice wild-type for Ube2f indicating improved growth

neoplasm

decreased tumor incidence ( J:348744 )

• decrease in pancreatic intraepithelial neoplasia at all 3 stages relative to mutant mice wild-type for Ube2f at 4, 6, and 9 months of age

• by 12 months of age there is an increase in stage I but decrease in stage II and III lesions in the pancreas indicating a delay in pancreatic tumor progression

endocrine/exocrine glands

small pancreas ( J:348744 )

• relative to mutant mice wild-type for Ube2f

decreased susceptibility to induced pancreatitis ( J:348744 )

• decrease in disruption of acinar cell population in cerulein-induced pancreatitis

• fewer infiltrations of leukocytes and neutrophils at 3d after cerulein treatment